Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation.
Cancer Invest
; 40(7): 654-662, 2022 Aug.
Article
in En
| MEDLINE
| ID: mdl-35770934
ABSTRACT
Despite the incorporation of trastuzumab biosimilars (to treat HER2-positive breast cancer) in clinical practice guidelines, gaps remain such as patient and clinician education. We hosted a webinar comprised of a panel of biosimilars experts, oncologists, pharmacist, infusion nurse, and a patient advocate. The outcomes of the webinar include audience responses to pre- and post-webinar questionnaires, educational benefits, real-time opportunities to ask questions, and a recording. Education needs to be tailored to the needs of both, patients and clinicians.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Biosimilar Pharmaceuticals
Type of study:
Guideline
/
Qualitative_research
Limits:
Female
/
Humans
Language:
En
Journal:
Cancer Invest
Year:
2022
Type:
Article
Affiliation country:
United States